Teva's Luck Continues To Run Out

Teva (TEVA) has been performing poorly over the last few years as its generics business has been declining in sales. It managed to beat its fourth quarter earnings, but stated that 2018 will be quite rocky. The lower guide along with many other problems that Teva currently faces continues to make it a good short opportunity.

Earnings Beat, But Still Down From Prior Year

Teva managed to beat its fourth quarter earnings. It posted adjusted earnings per share of $0.93 cents, compared to an expectation of $0.77 cents. Revenue came in at $5.46 billion compared to the expectation that it would earn $5.29 billion. Sounds good right? Well, it's not good at all. The reason why is because even though revenue came in above expectations, it still dropped from the same time period last year. Last year in the same period, revenue came in at $6.49 billion. That's approximately a 16% decrease in revenue year-over-year. The same issue can be said about EPS as well. Although Teva earned $0.93 cents per share, that's still down from the prior year where it had earned $1.38 per share. That is a percentage decrease of 32% year-over-year.

READ FULL ARTICLE HERE